- Home
- RCUS vs SANA Comparison
RCUS vs SANA Comparison
Compare RCUS & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- SANA
- Stock Information
- Founded
- RCUS 2015
- SANA 2018
- Country
- RCUS United States
- SANA United States
- Employees
- RCUS N/A
- SANA N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- RCUS Health Care
- SANA Health Care
- Exchange
- RCUS Nasdaq
- SANA Nasdaq
- Market Cap
- RCUS 1.2B
- SANA 983.4M
- IPO Year
- RCUS 2018
- SANA 2021
- Fundamental
- Price
- RCUS $13.90
- SANA $4.12
- Analyst Decision
- RCUS Buy
- SANA Strong Buy
- Analyst Count
- RCUS 7
- SANA 6
- Target Price
- RCUS $22.00
- SANA $8.00
- AVG Volume (30 Days)
- RCUS 937.9K
- SANA 3.8M
- Earning Date
- RCUS 11-05-2025
- SANA 11-07-2025
- Dividend Yield
- RCUS N/A
- SANA N/A
- EPS Growth
- RCUS N/A
- SANA N/A
- EPS
- RCUS N/A
- SANA N/A
- Revenue
- RCUS $262,000,000.00
- SANA N/A
- Revenue This Year
- RCUS N/A
- SANA N/A
- Revenue Next Year
- RCUS N/A
- SANA N/A
- P/E Ratio
- RCUS N/A
- SANA N/A
- Revenue Growth
- RCUS 6.07
- SANA N/A
- 52 Week Low
- RCUS $6.50
- SANA $1.26
- 52 Week High
- RCUS $18.98
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- RCUS 68.53
- SANA 68.83
- Support Level
- RCUS $12.89
- SANA $3.28
- Resistance Level
- RCUS $16.12
- SANA $3.58
- Average True Range (ATR)
- RCUS 0.73
- SANA 0.23
- MACD
- RCUS 0.07
- SANA 0.11
- Stochastic Oscillator
- RCUS 44.17
- SANA 90.98
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.